Literature DB >> 18079273

Long-term cardiovascular effects of neonatal dexamethasone treatment: hemodynamic follow-up by left ventricular pressure-volume loops in rats.

Miriam P Bal1, Willem B de Vries, Matthijs F M van Oosterhout, Jan Baan, Ernst E van der Wall, Frank van Bel, Paul Steendijk.   

Abstract

Dexamethasone is clinically applied in preterm infants to treat or prevent chronic lung disease. However, concern has emerged about adverse side effects. The cardiovascular short-term side effects of neonatal dexamethasone treatment are well documented, but long-term consequences are unknown. Previous studies showed suppressed mitosis during dexamethasone treatment, leading to reduced ventricular weight, depressed systolic function, and compensatory dilatation in prepubertal rats. In addition, recent data indicated a reduced life expectancy. Therefore, we investigated the long-term effects of neonatal dexamethasone treatment on cardiovascular function. Neonatal rats were treated with dexamethasone or received saline. Cardiac function was determined in 8-, 50-, and 80-wk-old animals, representing young adult, middle-aged, and elderly stages. A pressure-conductance catheter was introduced into the left ventricle to measure pressure-volume loops. Subsequently, the hearts were collected for histological examination. Our results showed reduced ventricular and body weights in dexamethasone-treated rats at 8 and 80 wk, but not at 50 wk. Cardiac output and diastolic function were unchanged, but systolic function was depressed at 50 and 80 wk, evidenced by reduced ejection fractions and rightward shifts of the end-systolic pressure-volume relationships. We concluded that previously demonstrated early adverse effects of neonatal dexamethasone treatment are transient but that reduced ventricular weight and systolic dysfunction become manifest again in elderly rats. Presumably, cellular hypertrophy initially compensates for the dexamethasone treatment-induced lower number of cardiomyocytes, but this mechanism falls short at a later stage, leading to systolic dysfunction. If applicable to humans, cardiac screening of a relatively large patient group to enable secondary prevention may be indicated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079273     DOI: 10.1152/japplphysiol.00951.2007

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  12 in total

1.  Dexamethasone Induces Cardiomyocyte Terminal Differentiation via Epigenetic Repression of Cyclin D2 Gene.

Authors:  Maresha S Gay; Chiranjib Dasgupta; Yong Li; Angela Kanna; Lubo Zhang
Journal:  J Pharmacol Exp Ther       Date:  2016-06-14       Impact factor: 4.030

2.  Cardiac proteasome activity in muscle ring finger-1 null mice at rest and following synthetic glucocorticoid treatment.

Authors:  Darren T Hwee; Aldrin V Gomes; Sue C Bodine
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-09       Impact factor: 4.310

Review 3.  Non-genomic effect of glucocorticoids on cardiovascular system.

Authors:  Sung Ryul Lee; Hyoung Kyu Kim; Jae Boum Youm; Louise Anne Dizon; In Sung Song; Seung Hun Jeong; Dae Yun Seo; Kyoung Soo Ko; Byoung Doo Rhee; Nari Kim; Jin Han
Journal:  Pflugers Arch       Date:  2012-09-23       Impact factor: 3.657

4.  Effects of neonatal dexamethasone administration on cardiac recovery ability under ischemia-reperfusion in 24-wk-old rats.

Authors:  Xinli Jiang; Huijie Ma; Chunguang Li; Yue Cao; Yan Wang; Yi Zhang; Yan Liu
Journal:  Pediatr Res       Date:  2016-03-18       Impact factor: 3.756

5.  Conductance catheter measurement and effect of different anesthetics in a rat model of postresuscitation myocardial dysfunction.

Authors:  Jürgen Knapp; Peter Teschendorf; Eberhard Scholz; Joachim Roewer; Nicolai Russ; Bernd W Böttiger; Erik Popp
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-07       Impact factor: 1.232

Review 6.  Binucleation of cardiomyocytes: the transition from a proliferative to a terminally differentiated state.

Authors:  Alexandra N Paradis; Maresha S Gay; Lubo Zhang
Journal:  Drug Discov Today       Date:  2013-10-31       Impact factor: 7.851

7.  Systemic maternal inflammation and neonatal hyperoxia induces remodeling and left ventricular dysfunction in mice.

Authors:  Markus Velten; Kirk R Hutchinson; Matthew W Gorr; Loren E Wold; Pamela A Lucchesi; Lynette K Rogers
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

Review 8.  Bronchopulmonary dysplasia early changes leading to long-term consequences.

Authors:  Anne Hilgendorff; Michael A O'Reilly
Journal:  Front Med (Lausanne)       Date:  2015-02-12

9.  Antioxidant treatment improves neonatal survival and prevents impaired cardiac function at adulthood following neonatal glucocorticoid therapy.

Authors:  Youguo Niu; Emilio A Herrera; Rhys D Evans; Dino A Giussani
Journal:  J Physiol       Date:  2013-08-12       Impact factor: 5.182

10.  SOD3 reduces inflammatory cell migration by regulating adhesion molecule and cytokine expression.

Authors:  Juha P Laurila; Lilja E Laatikainen; Maria D Castellone; Mikko O Laukkanen
Journal:  PLoS One       Date:  2009-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.